S&P DJI Announces September 2026 Quarterly Rebalance
Filed with ASX · · 6 pages · English
Story so far
Earlier from Immutep
- Appendix 4E & 2026 Full Year Statutory Accounts
- Immutep Corporate Presentation
- Immutep Quarterly Activities Report Q4 FY26
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Later from Immutep
- Immutep Outlines Focused Development Strategy for Efti
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
- Change to American Depositary Share Ratio
- Immutep receives Australian R&D Tax Incentive
- Immutep Receives ~A$0.86 Million R&D Tax Incentive
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep